{'fraction_non_alphanumeric': 0.015789473684210527, 'fraction_numerical': 0.0, 'mean_word_length': 5.65034965034965, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Prevention and treatment of residual neuromuscular blockade with doxapram during postoperative recovery.

Residual neuromuscular blockade and depression of respiratory function are very important in the postoperative period, and obesity is a risk factor. Thereby, the effective use of muscle relaxant antagonists with neuromuscular function monitoring is critical for the prevention of residual neuromuscular blockade and pulmonary adverse events. The analeptic agent, doxapram, is often used at the end of anaesthesia to stimulate ventilation and accelerate recovery from the effects of volatile anaesthetic agents without antagonising analgesia. We read with great interest the article by Fathi et al. entitled ‘The effects of doxapram on time to tracheal extubation and early recovery in young morbidly obese patients scheduled for bariatric surgery: A randomised controlled trial’. However, we do have some concerns that we would like to discuss.